The reimbursement criteria may be published in the form as therapeutic indications and it is the prescriber`s responsibility to prescribe the drug to odB recipients according to the stated criteria. Product list agreements allow ODB recipients access to new drugs, while information that may support a future list is being collected and verified. The level and differences in the use of the ALP in Canadian provinces have the potential to have a significant impact on drug price consistency and access across the country. Currently, however, no province publishes information on the use of ALP for all funded drugs. This lack of public information on the use of GPs to date makes it difficult to participate in an informed debate on this political instrument in Canada. Several authors have collected information on the types of negotiated agreements that have been tried in one or more provinces (Carlson et al. 2010; Nason and Sproule 2011; Stafinski et al. 2010). However, to our knowledge, no studies have systematically documented the use of ALP in Canada. We wanted to fill this gap in evidence by collecting information from all provinces on the use of ALP for a sample of drugs for which manufacturers have recently sought to cover themselves under provincial drug plans. Canadian Institute for Health Information (CIHI). Prescribed drug spending in Canada, 2013: the focus on public drug programs; 2013. Available from: secure.cihi.ca/free_products/Prescribed%20Drug%20Spending%20in 20Canada_2014_EN.pdf.
We consulted on March 11, 2016. In the absence of public data sources, we directly requested information on the use of the PLA from policy makers in each province. Due to the sensitive nature of APA information, we first consulted with policy makers to identify information that could and could be made public. In May 2012, we asked policy makers if they could disclose specific information about coverage, pla use and PLA (e.g. B, simple discounts, price-volume agreements or results-based pricing). After gathering information and feedback from the 10 provinces, in July 2012 we requested drug information for a drug sample that, in 2010 or 2011, received an initial recommendation on joint drug control (CDR) and was funded in one or more provinces at the time. A total of 35 drugs were first tested by the CDR between 2010 and 2011. We excluded nine of these drugs because as of May 2012, they were not listed in any province for coverage – and therefore would not generate data on PLA.
We also excluded a drug, Janumet, on the recommendation that confidentiality clauses for related APAs in some unmentioned provinces necessarily restrict participation in our study. All survey responses were collected anonymously with respect to important findings, areas of consensus and disagreement, and key points of interest. An analysis of the survey results was conducted and the results were shared with all interested participants at two web meetings. Abbreviations: COPD, chronic obstructive pulmonary disease; IPLAs, list agreements for innovative products.